Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Soluble recombinant cr-2 (cd21) inhibits epstein-barr virus-infection

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Nemerow, Glen
  • Mullen, J. J.
  • Dickson, P. W.
  • Cooper, N. R.

publication date

  • March 1990

journal

  • Journal of Virology  Journal

abstract

  • Epstein-Barr virus (EBV), an oncogenic herpesvirus of humans, displays selective tropism for B lymphocytes and epithelial cells. EBV tropism is thought to be determined in part by a unique host cell receptor termed CR2 (CD21). Although previous studies have demonstrated that CR2 mediates EBV binding to B cells, its role in initiating EBV infection and B-cell transformation is less certain. In the studies reported here, soluble recombinant CR2 was shown to cause substantial inhibition of EBV infection of B cells in vitro, indicating that CR2 binding initiates EBV infection. Soluble CR2 may represent a therapeutic agent for acute and chronic EBV infections in humans.

subject areas

  • Antigens, CD
  • Antigens, Differentiation, B-Lymphocyte
  • Antiviral Agents
  • B-Lymphocytes
  • Base Sequence
  • Genetic Vectors
  • Herpesvirus 4, Human
  • Humans
  • Molecular Sequence Data
  • Oligonucleotide Probes
  • Receptors, Complement
  • Receptors, Complement 3d
  • Receptors, Virus
  • Recombinant Proteins
scroll to property group menus

Identity

PubMed Central ID

  • PMC249254

International Standard Serial Number (ISSN)

  • 0022-538X

PubMed ID

  • 2154612
scroll to property group menus

Additional Document Info

start page

  • 1348

end page

  • 1352

volume

  • 64

issue

  • 3

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support